Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

References

• Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association. Washington, DC, USA (2000).
   Google Scholar
• Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress. Anxiety16, 162–171 (2002).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol.15, 445–452 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 593–602 (2005).
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Beesdo K et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry63(Suppl. 8), 24–34 (2002).
   PubMed Web of Science ®Google Scholar
• Beekman ATF, Bremmer MA, Deeg DJH et al. Anxiety disorders in later life: a report from the longitudinal aging study Amsterdam. Int. J. Geriatr. Psychiatry13, 717–726 (1998).
   PubMed Web of Science ®Google Scholar
• Noyes R Jr. Comorbidity in generalized anxiety disorder. Psychiatr. Clin. North Am.24, 41–55 (2001).
   PubMed Web of Science ®Google Scholar
• Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry156, 1915–1923 (1999).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Olfson M, Berglund PA. Patterns and predictors of treatment contact after first onset of psychiatric disorders. Am. J. Psychiatry155, 62–69 (1998).
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalized anxiety disorder. Br. J. Psychiatry176, 544–549 (2000).
   PubMed Web of Science ®Google Scholar
• Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry158, 1568–78 (2001).
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JRT. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol. Psychiatry44, 1286–1294 (1998).
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol.23, 240–249 (2003).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry3, 171–199 (2002).
   PubMedGoogle Scholar
• Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol.19, 567–596 (2005).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Nair RV. Escitalopram in the treatment of generalized anxiety disorder. Expert Rev. Neurother.5, 443–449 (2005).
   PubMedGoogle Scholar
• Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int. J. Neuropsychopharmacol.8, 293–302 (2005).
   PubMed Web of Science ®Google Scholar
• Frampton JE, Foster RH. Pregabalin in the treatment of generalized anxiety disorder. CNS Drugs20, 685–693 (2006).
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry50, 884–895 (1993).
   PubMed Web of Science ®Google Scholar
• Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk–benefit evaluation with a focus on extended-release alprazolam. J. Clin. Psychiatry63(Suppl. 14), 27–33 (2002).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: twenty-four week placebo-controlled dose-ranging study. Br. J. Psychiatry179, 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry157, 968–974 (2001).
   Google Scholar
• Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry160, 749–756 (2003).
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind placebo-controlled trials. J. Affect. Disord.87, 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl.)105, 428–432 (1991).
   PubMed Web of Science ®Google Scholar
• Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy5, 290–296 (1985).
   PubMedGoogle Scholar
• Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder. A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry62, 1022–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry67, 771–782 (2006).
   PubMed Web of Science ®Google Scholar
• Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder. Double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol.25, 151–158 (2005).
   PubMed Web of Science ®Google Scholar
• Errante LD, Petroff OAC. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure12, 300–306 (2003).
   PubMed Web of Science ®Google Scholar
• Belliotti TR, Capiris T, Ekhato IV et al. Structure-activity relationships of pregabalin and analogues that target the α2–δ1 protein. J. Med. Chem.48, 2294–2307 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel a2–d (alpha2–delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res.73, 137–150 (2007).
   PubMed Web of Science ®Google Scholar
• Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br. J. Pharmacol.132, 1–4 (2001).
   PubMed Web of Science ®Google Scholar
• Field MJ, Cox PJ, Stott E et al. Identification of the α2-δ1 subunit of voltage- dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. USA103, 17537–17542 (2006).
   PubMed Web of Science ®Google Scholar
• Vartanian MG, Radulovic LL, Kinsora JJ et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res.68, 189–205 (2006).
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2-δ subunit of a calcium channel. J. Biol. Chem.271, 5768–5776 (1996).
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology42, 229–236 (2002).
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett.280, 107–110 (2000).
   PubMed Web of Science ®Google Scholar
• Dooley DJ Donovan CM, Pugsley TA. Stimulus-dependent modulation of 3H-norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther.295, 1086–1093 (2000).
   PubMed Web of Science ®Google Scholar
• Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K+-evoked release of 3H-glutamate from rat caudal trigeminal nucleus slices. Pain93, 191–196 (2001).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain105, 133–141 (2003).
   PubMed Web of Science ®Google Scholar
• Corrigan BW, Pool WF, Posvar EL et al. Metabolic disposition of pregabalin in healthy volunteers. Clin. Pharmacol. Ther.69, 18 (2001) (Abstract PI-68).
   Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol.43, 277–283 (2003).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia46, 1407–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D. Pharmacokinetic (PK) profile of pregabalin shows minimal drug–drug interactions: results of a series of studies. Presented at American Psychiatric Association Annual Meeting. New York, NY, USA, 1–6 May 2004 (Abstract NR378).
   Google Scholar
• Bockbrader HN, Posvar EL, Hunt T, Randinitis EJ. Pregabalin does not alter the effectiveness of an oral contraceptive. Neurology62(Suppl. 5), A314 (2004) (Abstract P04.097).
   Google Scholar
• Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry160, 533–540 (2003).
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Janney C et al. Three randomised, placebo-controlled double-blind trials of pregabalin treatment of generalised anxiety disorder (GAD). Int. J. Neuropsychopharmacol.3(Suppl. 1), S344 (2000) (Abstract P.3.025).
   Google Scholar
• Montgomery SA, Chalmers K, Baldinetti F, Whalen E. Efficacy and safety of pregabalin for the treatment of generalized anxiety disorder in elderly patients (Poster). Proceedings of the 19th European College of Neuropsychopharmacology Congress. Nice, France, 16–20 September 2006.
   Google Scholar
• Feltner D, Wittchen H-U, Kavoussi R, Brock J, Baldinetti F, Pande AC. Efficacy of pregabalin in preventing relapse in the long-term treatment of generalized anxiety disorder. Int. Clin. Psychopharmacol. (2007) (In Press).
   Google Scholar
• Montgomery SA. Pregabalin for the treatment of generalized anxiety disorder. Expert Opin. Pharmacother.7, 2139–2154 (2006).
   Google Scholar
• Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacol.183, 133–143 (2005).
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects of pregabalin compared with alprazolam and placebo. Sleep28, 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat.11, 9–21 (2001).
   PubMedGoogle Scholar
• Wittchen H-U. Pregabalin in the treatment of generalized anxiety disorder. A viewpoint by Hans-Ulrich Wittchen. CNS Drugs20, 694 (2006).
   Google Scholar